DeepMed Research

AGENUS INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence

Phase 2

Terminated

Conditions: Renal Cell Carcinoma

Interventions: Biological: HSPPC-96

First Posted Date: 2010-06-22

Last Posted Date: 2021-06-03

Lead Sponsor: Agenus Inc.

Target Recruit Count: 12

Registration Number: NCT01147536

Locations: 🇺🇸
Community Care Physicians, Albany, New York, United States
🇨🇦
Pavillion de Recherche de Hotel Dieu, Quebec, Canada
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma

Phase 1

Completed

Conditions: Malignancies
B-Cell Lymphoma

First Posted Date: 2006-04-21

Last Posted Date: 2008-10-27

Lead Sponsor: Agenus Inc.

Target Recruit Count: 21

Registration Number: NCT00316511

Trial Evaluating Safety, Tolerability and Immune Response of AG-707

Phase 1

Completed

Conditions: Genital Herpes

First Posted Date: 2005-10-04

Last Posted Date: 2008-10-27

Lead Sponsor: Agenus Inc.

Target Recruit Count: 35

Registration Number: NCT00231049

Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer

Phase 3

Terminated

Conditions: Kidney Cancer
Renal Cell Carcinoma

First Posted Date: 2005-08-03

Last Posted Date: 2012-09-07

Lead Sponsor: Agenus Inc.

Target Recruit Count: 600

Registration Number: NCT00126178

Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-Small-Cell Lung Carcinoma
Lung Cancer
Pulmonary Cancer

First Posted Date: 2004-12-06

Last Posted Date: 2009-03-09

Lead Sponsor: Agenus Inc.

Target Recruit Count: 20

Registration Number: NCT00098085

Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma

Phase 2

Terminated

Conditions: Renal Cell Carcinoma

First Posted Date: 2004-05-12

Last Posted Date: 2012-09-07

Lead Sponsor: Agenus Inc.

Target Recruit Count: 40

Registration Number: NCT00082459

A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma

Phase 2

Completed

Conditions: Lymphoma, Follicular
Lymphoma, Small Lymphocytic

First Posted Date: 2004-04-23

Last Posted Date: 2023-09-28

Lead Sponsor: Agenus Inc.

Target Recruit Count: 35

Registration Number: NCT00081809

Locations: 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States

AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™

Phase 2

Terminated

Conditions: Leukemia, Myeloid, Chronic

First Posted Date: 2003-04-15

Last Posted Date: 2012-09-07

Lead Sponsor: Agenus Inc.

Target Recruit Count: 40

Registration Number: NCT00058747

Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma

Phase 3

Completed

Conditions: Malignant Melanoma

First Posted Date: 2002-06-10

Last Posted Date: 2012-09-07

Lead Sponsor: Agenus Inc.

Target Recruit Count: 350

Registration Number: NCT00039000

Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer

Phase 3

Completed

Conditions: Renal Cell Carcinoma

First Posted Date: 2002-04-15

Last Posted Date: 2012-09-07

Lead Sponsor: Agenus Inc.

Target Recruit Count: 650

Registration Number: NCT00033904

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy